Physician profile
Amber M Patterson
NPI 1104082957
$128,267.85
in general payments reported to CMS, 2019-2025
34 companies · $58K in 2025
The $58K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $13K · 2021: $9,428 · 2022: $6,370 · 2023: $4,902 · 2024: $21K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $14K · Food and Beverage: $7,912 · Consulting Fee: $4,883 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,650.00 |
| Travel and Lodging | $14,367.76 |
| Food and Beverage | $7,911.77 |
| Consulting Fee | $4,883.36 |
| Education | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $62,941.77 | 2020-2025 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $39,727.51 | 2025 | Neffy |
| Shire North American Group INC | $12,165.95 | 2019 | |
| Optinose US, INC. | $3,313.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,678.70 | 2020-2025 | Cuvitru, Hyqvia, Glassia |
| Kaleo, INC. | $1,859.32 | 2020-2024 | Auvi-Q |
| Amgen INC. | $854.24 | 2023-2025 | Tezspire |
| Astrazeneca Pharmaceuticals Lp | $811.45 | 2020-2025 | Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $601.98 | 2019-2025 | Dupixent |
| Pfizer INC. | $486.16 | 2023-2025 | |
| Genzyme Corporation | $389.58 | 2023-2025 | |
| Csl Behring | $348.01 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $261.30 | 2023-2025 | |
| Gc Biopharma USA, INC. | $200.89 | 2024-2025 | Alyglo, Alyglo |
| Grifols USA, LLC | $198.75 | 2023-2025 | Xembify, Prolastin-C Liquid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $188.31 | 2023-2025 | Orladeyo |
| Adma Biomanufacturing LLC | $170.86 | 2023-2025 | |
| Genentech USA, INC. | $161.18 | 2022-2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $153.98 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2024 | Ultomiris |
| Aquestive Therapeutics, INC. | $123.00 | 2025 | |
| Dexcom, INC. | $95.00 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Alk-Abello, INC | $85.07 | 2021-2023 | Ragwitek, Odactra, Grastek |
| Greer Laboratories, INC. | $61.74 | 2024-2025 | Palforzia, Oralair |
| Blueprint Medicines Corporation | $60.41 | 2023 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $38.40 | 2023 | Reblozyl |
| Lexicon Pharmaceuticals, INC. | $35.00 | 2023 | Inpefa |
| Novo Nordisk INC | $35.00 | 2025 | Wegovy |
| Argenx US, INC. | $34.45 | 2024 | Vyvgart Hytrulo |
| Octapharma USA, INC. | $23.38 | 2023 | Cutaquig |
| Galderma Laboratories, L.P. | $19.56 | 2025 | Nemluvio |
| Phadia US INC. | $18.30 | 2024 | Immunocap |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.